An assay to monitor the activity of DNA transposition complexes yields a general quality control measure for transpositional recombination reactions

Elsi Pulkkinen, Saija Haapa-Paananen, and Harri Savilahti*

Division of Genetics and Physiology; Department of Biology; University of Turku; Turku, Finland

Keywords: ccdB gene, phage Mu, transposition activity measurement, transposon technology, transpososome

Abbreviations: Ap, Ampicillin; CFU, colony forming units; Cm, Chloramphenicol; Km, Kanamycin

Transposon-based technologies have many applications in molecular biology and can be used for gene delivery into prokaryotic and eukaryotic cells. Common transpositional activity measurement assays suitable for many types of transposons would be beneficial, as diverse transposition systems could be compared for their performance attributes. Therefore, we developed a general-purpose assay to enable and standardize the activity measurement for DNA transposition complexes (transpososomes), using phage Mu transposition as a test platform. This assay quantifies transpositional recombination efficiency and is based on an in vitro transposition reaction with a target plasmid carrying a lethal ccdB gene. If transposition targets ccdB, this gene becomes inactivated, enabling plasmid-receiving Escherichia coli cells to survive and to be scored as colonies on selection plates. The assay was validated with 3 mini-Mu transposons varying in size and differing in their marker gene constitution. Tests with different amounts of transposon DNA provided a linear response and yielded a 10-fold operational range for the assay. The colony formation capacity was linearly correlated with the competence status of the E.coli cells, enabling normalization of experimental data obtained with different batches of recipient cells. The developed assay can now be used to directly compare transpososome activities with all types of mini-Mu transposons, regardless of their aimed use. Furthermore, the assay should be directly applicable to other transposition-based systems with a functional in vitro reaction, and it provides a dependable quality control measure that previously has been lacking but is highly important for the evaluation of current and emerging transposon-based applications.

Introduction

Transposable genetic elements are discrete segments of DNA capable of moving between different chromosomal locations in their host’s genome or between different genomes. DNA transposons form a class of elements that use a special form of DNA recombination for their movement, called transpositional recombination or transposition, and this process is not dependent on sequence homology between the transposon DNA and a target site. As transposons move from one locus to another, they supply new genetic material and provoke genome instability, unavoidably influencing the evolution of organisms. Transposable elements (TEs) have been found to exist in almost every organism studied so far, although the fraction of the genome that they cover varies among species. For instance, 45% of the human genome and 85% of the maize genome are related to TEs. In contrast to eukaryotes, prokaryotic genomes commonly carry moderate numbers of transposons, although the number of TEs can vary greatly even between closely related strains of a species. The inherent capability of transposons to break and rejoin DNA have enabled the construction of a diverse set of efficient molecular tools, which can be utilized for both single gene and whole genome studies. Applications based on transposable elements include insertional mutagenesis, genome manipulation and transgenesis, functional genomics studies, gene therapy, and generation of induced pluripotent stem cells.
transposon-based methodologies are currently under active development, and novel applications are expected to emerge in the near future.

Traditionally transposon-based applications were based on in vivo transposition reactions, in which the reaction needs either mobilization of an endogenous transposon or introduction of a transposon-containing plasmid. Increased understanding on transposition mechanisms has enabled the establishment of in vitro systems for many types of transposons. Typical prokaryotic examples include the in vitro reactions of Tn3, Tn5, Tn7, Tn10, Tn552, IS911, ISY100, IS608, and bacteriophage Mu. In vitro transposition systems developed for eukaryotic transposons include e.g. the in vitro reactions of yeast Ty1, mariner/Tc1 family transposons Tc1, Himar1, and Mos1; piggyBac; and hAT superfamily transposon Hermes.

Bacteriophage Mu was the first transposition system, for which an in vitro transposition reaction was established. This phage uses two modes of DNA transposition during its life cycle: (i) upon infection it integrates without replication into its host genome, and (ii) during lytic growth it uses replicative transposition to produce copies of itself. Mu DNA transposition proceeds through transposition complexes or transpososomes, that are formed when MuA transposase proteins initially bind to sequence-specific binding sites in the transposon ends, after which a transpositionally active protein-DNA complex, Mu transpososome, is formed. While Mu transposition in a natural context is a complex process, a substantially simplified version of the reaction can be reproduced in vitro. In the minimal reaction, only MuA transposase protein, transposon DNA, and target DNA are required. This minimal in vitro reaction has proven to be highly efficient, and it has a low target site selectivity. To date, Mu transposition reaction has been utilized in a variety of molecular biology, protein engineering, and genomics applications, and also for efficient gene delivery in bacteria, yeast, and mammalian cells.

Although in vitro transposition reactions have been widely used in various applications, a universal activity measurement assay to quantify transpositional activity is lacking. A single assay utilizing a common target, and applicable to all types of different transposons, with a functional in vitro reaction, would allow a direct comparison of transpositional activities within or between particular experimental systems. We therefore developed an assay for the standardization of the measurements on transpositional activity. It is well-suited for all types of transposons and particularly useful with transposons that do not contain selectable marker genes or contain markers functional only in eukaryotic cells.

**Results**

**Assay design**

All transposon-based technologies would greatly benefit from a single activity measurement assay to quantify transposition. To meet this demand for quality control, we used phage Mu DNA transposition as a test platform and set up an in vitro transposition assay that utilizes plasmid pZErO-2 as the target for transposition (Fig. 1). This plasmid contains a kanamycin resistance cassette for selection in E. coli and a lethal ccdB gene for direct selection of insertions. Expression of CcdB protein in wild type E. coli cells causes cell death by inhibiting DNA gyrase, an essential enzyme that generates negative supercoils in DNA. A transposon insertion into ccdB inactivates the gene, allowing the propagation of the plasmid. In this study, preassembled transpososomes are mixed with pZErO-2 target plasmid and incubated to generate transposition reaction products. The products are then introduced into E. coli cells by transformation, and the cells are selected for kanamycin resistance. The colonies scored represent events where ccdB in the target plasmid has been inactivated.

**Validating assay procedure**

To evaluate general properties of the assay, we performed in vitro transposition reactions with MuA transposase, Cat-Mu transposon DNA (encoding chloramphenicol resistance), and pZErO-2 target plasmid (encoding kanamycin resistance); transformed the transposition reaction products into DH10B and DB3.1 E. coli cells; and compared the results between the two strains (Table 1.). DB3.1 allows pZErO-2 propagation, as it
encodes the antidote for the lethal \textit{ccdB} gene. Reactions incubated without MuA transposase did not produce colonies, whereas reactions with MuA yielded chloramphenicol and kanamycin double resistant colonies ($6 \times 10^3 - 1 \times 10^4 \text{ CFU/\mu g target DNA}$) with pZErO-2 target plasmid and chloramphenicol and ampicillin double resistant colonies ($2 \times 10^1 - 7.73 \times 10^5 \text{ CFU/\mu g DNA}$) with pUC19 control plasmid (not harboring a lethal gene). As only the samples that had been incubated with MuA yielded colonies on double selection plates, the result indicates that the scored colonies resulted from transposon integration into the target plasmids. The number of colonies obtained from the pZErO-2 target plasmid reactions with DH10B recipient cells varied only slightly on different selection plates (kanamycin, chloramphenicol, double selection), verifying that all of these colonies originated from Cat-Mu integrations into pZErO-2. The reactions without MuA transposase incubation with pZErO-2 target plasmid produced a large number ($8 \times 10^5 \text{ CFU/\mu g DNA}$) of kanamycin resistant colonies with the antidote-encoding DB3.1 strain, while the standard laboratory strain DH10B produced only few colonies ($2 \times 10^1 \text{ CFU/\mu g DNA}$). Thus, the frequency of spontaneous ccdB-inactivating mutations ($2.6 \times 10^{-5}$) is negligible, and therefore it has no significance for the utility of the assay.

### Validating applicability with mini-Mu transposons

To test the applicability of the assay, we set up a time course experiment using 3 different transposons (Fig. 1). Mu transpososomes were assembled by incubating the Cat-Mu (encoding chloramphenicol resistance gene), Kan/Neo-Mu (encoding kanamycin resistance gene), and Puro-eGFP-Mu (encoding no antibiotic resistance gene for bacteria) transposons with MuA protein for different periods of time (0, 10, 60, 120, 240 minutes). An aliquot of each assembly reaction from different time points was then incubated with pZErO-2 target plasmid.

![Figure 2. Validating applicability with mini-Mu transposons.](image-url) Transposons used in the study: Cat-Mu (size 1.3 kb, contains chloramphenicol resistance marker), Kan/Neo-Mu (size 1.9 kb, contains kanamycin resistance marker) and Puro-eGFP-Mu (size 2.1 kb, no antibiotic resistance marker for bacteria). Transposon DNA was incubated with MuA transposase for different periods of time (0, 10, 60, 120, 240 minutes). In vitro transposition reactions with pZErO-2 and Cat-Mu transpososomes from different time points (0–240 minutes of incubation) were transformed into \textit{E. coli} strain DH10B and selected against kanamycin resistance. Results with the mean and standard deviation are shown for 3 replicates. Cat-Mu is shown in green, Kan/Neo-Mu in red, and Puro-eGFP-Mu in blue.
for 5 minutes, MgCl₂ was then added to initiate strand transfer, and the reactions were let to proceed for 2 minutes, after which the in vitro transposition reaction products were transformed into E. coli DH10B cells (Fig. 2.). Bacterial clones were selected for kanamycin resistance, and the colonies produced were enumerated to reveal the relative amount of transposition reaction products for each time point. The experiment was thus designed to quantify assembled functional transpososomes. With all the three transposons, the number of colonies increased rapidly following the initiation of incubation, and the number reached a matching level following 4 hours of incubation. The assembly was somewhat slower with the 2 longer transposons, but otherwise all the three transposons used yielded very similar results, illustrating the assay’s suitability for transposons differing in their marker composition.

**Defining operational range**

The general applicability of the assay requires functionality over a wide DNA range. To assess this, we used different amounts of transpososomes in the assay. The critical aspects evaluated were: (i) is the number of colonies sufficient for a reliable activity measurement even with a small amount of transpososomes, and (ii) does the amount of transpososomes correlate linearly with the number of colonies produced. Initially, we assembled Cat-Mu transpososomes for 4 hours, after which they were concentrated 10-fold, yielding a final concentration of 520 ng/ml for transposon DNA. Different amounts of this preparation were then used in the assay (Fig. 3). The highest amount of transpososomes (520 ng transposon DNA) yielded almost 1.8 × 10⁴ kanamycin resistant colonies, and the reaction with the most diluted sample (40 ng transposon DNA) produced 1.4 × 10³ colonies. The number of colonies increased linearly with the amounts of transpososomes tested, indicating at least a 10-fold dynamic range for the activity measurement assay.

**Influence of competence status**

The competence status of recipient cells is one factor influencing the number of colonies produced following transformation of in vitro transposition reaction products into competent E. coli cells. To define whether there is a correlation between colony formation and competence status of E. coli cells, we transformed transposition products from Cat-Mu in vitro reaction into different batches of competent DH10B E. coli cells (Fig. 4). The efficiency of these competent cells varied from ~1 × 10⁷ to 7 × 10⁷ (CFU/µg pUC19 DNA). The number of colony-forming cells with transposon-tagged target plasmids increased linearly with the competence status of the E. coli cells used. Thus, as expected, the capacity for colony formation correlated with the competence status of the recipient cells, enabling comparison of results obtained with different cell batches.

**Discussion**

A variety of in vitro DNA transposition reactions have provided a general methodology arsenal for functional genetic analyses and molecular biology applications. The integration events into target plasmids can be scored by introducing products from in vitro reactions into E. coli cells by transformation. Transposon insertion events are usually scored by the use of antibiotic selection, selecting simultaneously for transposon and target plasmid resistance markers. Although these types of assays have performed well in the context, in which they have been used, they are limited to transposons with suitable bacterial markers. This excludes the activity measurement of transposons without selectable markers or those constructed solely for eukaryotic use. Furthermore, the selection is dependent on the marker each particular transposon carries, which is not an ideal situation when comparing the activities of different transposons.

The assay developed in this study facilitates and standardizes the product analyses of various in vitro transposition reactions, as a common target plasmid (pZErO-2) and selection (for kanamycin resistance) is used regardless of the transposons employed.

The selection vector pZErO-2 has originally been designed to be used as a cloning vector, but it can also be used as a target
plasmid selecting for DNA transposition events. Previously it has been used in demonstrating the relation between transposition and V(D)J recombination, and for investigating the process of non-homologous end-joining. It contains a lethal gene ccdB, and following selection toward the antibiotic resistance encoded by the vector, only those cells which contain an interrupted ccdB gene will survive. The lethal ccdB gene region constitutes approximately one fourth of pZErO-2, and therefore, in our setup, on the average, one fourth of transposon insertions into it will become visible as colonies following transformation.

The frequency of spontaneous ccdB mutations resulting in the host survival and thus false positive colonies is 10^-5, as shown by the transformation of selective host cells with pZErO-2 and analogous pKIL plasmids, and our results conform with these observations. Single-ended transposon insertion events into ccdB may potentially produce false positive colonies if erroneous DNA repair processes generate a lesion at the original transposon end integration site. Although such mutagenic repair probably is very rare in E. coli, the issue needs to be kept under consideration if the assay is used with a transposition system producing a large fraction of single-ended integrations. With Mu transposition this is of no concern, as the frequency of one-ended integrations is negligible under standard in vitro reaction conditions with wild type MuA.

The applicability of the assay was demonstrated with three different transposons in a time course experiment, in which transposition reaction products yielded colonies. Comparisons between different transposons showed that with Cat-Mu (1.3 kb), the amount of reaction products increased faster than with Puro-eGFP-Mu (2.1 kb) and Kan/Neo-Mu (1.9 kb). However, with longer incubation times the differences evened out. The observed differences between different transposons most probably originate from size differences, and one explanation is that with longer transposons the assembly of transposition complexes occurs slower than with shorter transposons. It has been shown that as the transposon length increases, transposition efficiency decreases. This phenomenon is known as length-dependence, and it has been studied with several transposons, including Mu. There are several possible explanations for length-dependence that have not been well studied. The transposition complex formation may be more difficult with longer DNA fragments, or the transformation efficiency may be less powerful for larger complexes. It has been also proposed that the length-dependence could be due to suicidal autointegration (intramolecular transposition), suggesting that the transposon may be more prone to insert into itself as the length increases. Our results (Fig. 2) show that the assembly of transposition complexes with the longer transposons Puro-eGFP-Mu (2.1 kb) and Kan/Neo-Mu (1.9 kb) is somewhat slower than that with the shorter transposon Cat-Mu (1.3 kb). However, since the transposons that we used in this study were all relatively short, to be able to draw any further conclusions on the effect of transposon length, further studies are warranted with appropriate sets of longer transposons. Comparable colony numbers were obtained, regardless whether transposition events were selected toward kanamycin marker encoded by the transposon (Kan/Neo-Mu) in addition to the ccdB gene, or solely by the ccdB gene (Puro-eGFP-Mu). These results prove that the assay is suitable for various transposons with different selection markers, and therefore it is especially suitable for transposons containing solely eukaryotic marker genes or entirely lacking markers. Our activity measurement assay gave very similar results as compared to a previous study where Cat-Mu transposon was analyzed, showing that the data from the activity measurement assay is consistent with the earlier data.

The operational range of the assay was defined by using different quantities of Cat-Mu transposition complexes in in vitro transposition reactions (Fig. 3.). The amount of colonies increased linearly with the amount of transposon DNA (from 40 to 520 ng of transposon DNA per in vitro transposition reaction). The results showed that the adjustability of the assay spans a wide range of DNA concentrations, generating at least a 10-fold dynamic range.

Several batches of DH10B E. coli strain with different competence status were used to determine the effect of the competence status variation when transforming in vitro transposition reaction products into standard competent cells. The capacity for colony formation correlated linearly with the competence status, enabling normalization and therefore comparisons between the results with different batches of competent cells. The reaction products could as well be electrotransformed into electrocompetent cells, although then the variation between transformations presumably would be greater, somewhat reducing the reliability of the data.

We have established a general activity measurement assay that has been shown to be functional to quantify Mu transposition complexes. The assay measures transposition end products and provides a flexible and simple tool for measuring and comparing
the activity of different transpososome preparations regardless of the selection marker the transposon carries. Thus, it will ease particularly the evaluation of transposons containing solely eukaryotic selection markers. In addition to measuring the activity of preassembled transposition complexes, it can as well be used in the context of in vitro transposition reactions without prior complex assembly. Even though the developed assay has been shown to be functional with Mu transposons, it should be applicable to quantify in vitro reaction products of any other transposon with an established in vitro system. We envision that the developed assay could be regarded as a dependable quality control measure for various in vitro DNA transposition technology applications, including those aimed for mammalian genetics research and future gene therapy.

Methods

Bacteria, plasmids, and transposons

The target plasmid in activity measurements was pZErO-2 (Invitrogen by Life Technologies), and the control plasmid was pUC19 (New England Biolabs). E. coli strains DH10B and DB3.1 (Invitrogen by Life Technologies) were used for transformations. Transposons have been described earlier: Cav-Mu, 1.3 kb, Kan/Neo-Mu, 1.9 kb, and Puro-eGFP-Mu, 2.1 kb.57 Each transposon was released from its corresponding vector plasmid by BglII digestion that leaves 4 nucleotide 5’-overhangs, generating a precut end configuration. Following digestion transposons were purified using anion exchange chromatography as described.24 All three transposons contain a 50-bp Mu right end segment (including R1 and R2 MuA binding sites) at their termini. As a selectable marker, Cat-Mu contains the gene for chloramphenicol resistance, Kan/Neo-Mu for kanamycin/neomycin resistance, and Puro-eGFP-Mu for puromycin resistance. Cat-Mu is selectable in E. coli and Puro-eGFP-Mu in eukaryotic cells. Kan/Neo-Mu is selectable both in E. coli and eukaryotic cells.

Competent cells

Competent E. coli cells were prepared essentially as described.74 Briefly: E. coli cells were grown over night in Luria-Bertani (LB) medium. The culture was diluted 1/100 in a total volume of 250 ml with SOC medium and grown to an optical density at 600 nm of 0.4. Cells were harvested by centrifugation at 3000 rpm in a Sorvall GSA rotor at 4°C for 10 minutes. The cell pellet was resuspended in 100 ml of ice-cold buffer (100 mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2, 15% glycerol). Following centrifugation at 3500 rpm for 15 minutes, the cell pellet was resuspended in 4 ml of ice-cold buffer (75 mM CaCl2, 10 mM RbCl, 10 mM MOPS, 15% glycerol). The cells were incubated on ice for 1 h, frozen as aliquots using liquid nitrogen, and stored at −80°C.

Reagents and enzymes

MuA transposase was from Finnzymes, PEG6000 was from J. T. Baker, Triton X-100 from Fluka, Glycerol from BDH, DTT from Sigma, and EDTA from Gibco. Culture media for bacteria were from Scharlau.

Transpososome assembly and concentration of transpososomes

The in vitro transpososome assembly was conducted as previously described.50 The assembly reaction (80 μl) contained 4.4 pmol transposon DNA, 19.6 pmol MuA, 150 mM Tris-HCl pH 6, 50 % (v/v) glycerol, 0.025 % (w/v) Triton X-100, 150 mM NaCl and 0.1 mM EDTA. The reaction was carried out at 30°C for 4 hours, unless otherwise stated in the text. A successful assembly of transpososomes was verified using agarose/BSA/heparin gels as previously described.56 Transpososomes were concentrated using polyethylene glycol (PEG 6000) precipitation as described in.58,75 Storage buffer for concentrated complexes contained 10 mM Tris-HCl pH 6, 0.5% glycerol, and 0.1 mM DTT.

In vitro transposition reactions with preassembled transposition complexes and transformation of complexes into E. coli cells

The in vitro transposition reaction was done as previously described.39 The reaction (19 μl) contained variable amount of transpososomes as specified in each experiment, 2 μg of target DNA pZErO-2, 25 mM Tris pH 8.0, 110 mM NaCl, 0.05 % (w/v) Triton X-100, and 10 % (w/v) glycerol. The reaction was first incubated for 5 minutes at 30°C, and following the addition of one microliter of 200 mM MgCl2, incubation was continued for 2 minutes at 30°C. The reaction was terminated by incubation at 75°C for 10 minutes. The transposition reaction products (5 μl) were transformed into E. coli cells (100 μl). Following transformation, 900 μl of LB medium was added, and bacteria were grown for 50 minutes at 37°C on 220 rpm shaking and plated on chloramphenicol (10 μg/ml), kanamycin (25 μg/ml), or double selection plates.

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Tomi Mäkelä (University of Helsinki, Institute of Biotechnology, Helsinki, Finland) for providing the E. coli strain DB3.1 and Keith Derbyshire (University of Albany, Albany, NY, USA) for providing the E. coli strain DH10B. Tarjana Saarinen is acknowledged for technical assistance. Funding for the studies was obtained from Jenny and Antti Wihuri foundation (to EP), Oskar Öflund foundation (to EP), the University of Turku Graduate School (to EP), and the Academy of Finland (to HS).

Funding

This work was supported by the Academy of Finland (Grant 251168), Jenny and Antti Wihuri foundation, Oskar Öflund foundation, and the University of Turku Graduate School.
51. Poussu E, Vilhunen M, Paulin L, Savilahti H. Probing the a-complementing domain of E. coli b-galactosidase with use of an insertional pentapeptide mutagenesis strategy based on Mu in vitro DNA transposition. Proteins 2004; 54:681-92; PMID:14997564; http://dx.doi.org/10.1002/prot.10467

52. Poussu E, Jäättelä M, Savilahti H. A gene truncation strategy generating N- and C-terminal deletion variants of proteins for functional studies: Mapping of the Sec1p binding domain in yeast Mga1p by a Mu in vitro transposition-based approach. Nucleic Acids Res 2005; 33: e104; PMID:16006618; http://dx.doi.org/10.1093/nar/gni102

53. Kijlstra S, Vilen H, Poujanne M, Savilahti H, Skurnik M. Nonessential genes of phage YeO12-1 include genes involved in adaptation to growth on Yersinia enterocolitica serotype O:3. J Bacteriol 2005; 187:1405-14; PMID:15687205; http://dx.doi.org/10.1128/JB.187.4.1405-14.2005

54. Krupovic M, Vilen H, Bamford JK, Kivelä M, Aalto J, Kassinen A, Paulin L, Savilahti H. A strategy based on Mu in vitro DNA transposition complexes of bacteriophage Mu in yeast and mammalian genomes. Nucleic Acids Res 2008; 36:e148; PMID:18953026; http://dx.doi.org/10.1093/nar/gkn801

55. Poujanne MI, Poujanne AT, Finnie J, Savilahti H. Generation of transposon insertion mutant libraries for gram-positive bacteria by electroporation of phage Mu DNA transposition complexes. Microbiology 2005; 151:1209-18; PMID:15817788; http://dx.doi.org/10.1099/mic.0.27807-0

56. Wu Z, Xuanyuan Z, Li B, Jiang D, Li C, Xu H, Bai Y, Zhang X, Turakainen H, Saris PE, et al. Mu transposition complex mutagenesis in lactococcus lactis-identification of genes affecting nisin production. J Appl Microbiol 2009; 106:41-8; PMID:19128610; http://dx.doi.org/10.1111/j.1365-2672.2008.03962.x

57. Paatero AO, Turakainen H, Saris PE, et al. Mu transposition complexes are used to generate N- and C-terminal deletion variants of the a-complementing domain of E. coli by electroporation of phage Mu DNA transposition complexes. Microbiology 2005; 151:1209-18; PMID:15817788; http://dx.doi.org/10.1099/mic.0.27807-0

58. Wieland F, Matheron M, Caudin F, et al. Mu transposon-based mutagenesis of transposable DNAs from bacteriophage Mu in yeast and mammalian genomes. Nucleic Acids Res 2008; 36:e148; PMID:18953026; http://dx.doi.org/10.1093/nar/gkn801

59. Wu Z, Xuanyuan Z, Li B, Jiang D, Li C, Xu H, Bai Y, Zhang X, Turakainen H, Saris PE, et al. Mu transposition complex mutagenesis in lactococcus lactis-identification of genes affecting nisin production. J Appl Microbiol 2009; 106:41-8; PMID:19128610; http://dx.doi.org/10.1111/j.1365-2672.2008.03962.x

60. Bernard P, Couturier M. Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes. J Mol Biol 1992; 226:735-45; PMID:1324324; http://dx.doi.org/10.1006/jmbi.1993.1609

61. Bernard P, Gabant P, Bahassi EM, Couturier M. Positive-selection vectors using the F plasmid ccdB killer gene. Gene 1994; 148:71-4; PMID:7926841; http://dx.doi.org/10.1016/0378-1119(94)90235-6

62. Invitrogen by Life Technologies. Zero Background TM/Blue-Gal Cloning Kit. Carlsbad, California; Invitrogen by Life Technologies; 2012.

63. Bernard P, Kediz KE, Van Melderen L, Steyaert J, Wyns L, Patot ML, Higgins PN, Couturier M. The F plasmid CcdB protein induces efficient ATP-dependent DNA cleavage by gyrase. J Mol Biol 1993; 234:534-41; PMID:8254658; http://dx.doi.org/10.1006/jmbi.1993.1609

64. Hiom K, Melek M, Gellert M. DNA transposition by the HIMar1 mariner transposon in yeast. Genetics 1998; 149:179-87; PMID:9584095

65. Tachibana A. Genetic and physiological regulation of non-homologous end-joining in mammalian cells. Adv Biophys 2004; 38:21-44; http://dx.doi.org/10.1016/S0005-227X(04)80046-7

66. Bernard P. Positive selection of recombinant DNA by CcdB. BioTechniques 1996; 21:320-3; PMID:8862819

67. Way JC, Kleckner N. Transposition of plasmid-borne Tn10 elements does not exhibit simple length-dependence. Genetics 1985; 111:705-13; PMID:2998922

68. Lampe DJ, Gratz TE, Robertson HM. Factors affecting transposition of the Himar1 mariner transposon in vitro. Genetics 1998; 149:179-87; PMID:9584095

69. Grant SG, Jesse J, Bloom FR, Hanahan D. Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc Natl Acad Sci USA 1990; 87:4645-9; PMID:2162051; http://dx.doi.org/10.1073/pnas.87.12.4645

70. Bamborough RJ, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press; 2001.

71. Savilahti H, Bamford DH. Protein-prime DNA replication: Role of inverted terminal repeats in the escherichia coli bacteriophage PRD1 life cycle. J Virol 1993; 67:6906-703; PMID:8351725

72. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press; 2001.